تفاصيل الأصول
هل ترغب في حجز الكتاب؟
Teprotumumab for Thyroid-Associated Ophthalmopathy
لقد وضعنا الحجز لك!
بالمناسبة ، لماذا لا تستكشف الفعاليات التي يمكنك حضورها عند زيارتك للمكتبة لإستلام كتبك
هل أنت متأكد أنك تريد إزالة الكتاب من الرف؟
Teprotumumab for Thyroid-Associated Ophthalmopathy
هل تريد طلب الكتاب؟
Teprotumumab for Thyroid-Associated Ophthalmopathy
يرجى العلم أن الكتاب الذي طلبته لا يمكن استعارته. إذا كنت ترغب في إستعارة هذا الكتاب ، يمكنك حجز نسخة أخرى
Journal Article
Teprotumumab for Thyroid-Associated Ophthalmopathy
2017
نظرة عامة
In patients with thyroid-associated ophthalmopathy, responses to treatment are rare and usually minor. Teprotumumab, an antibody to the insulin-like growth factor I receptor, led to significant responses in 69% of patients and to decreased proptosis.
Medical therapies for moderate-to-severe thyroid-associated ophthalmopathy (Graves’ orbitopathy) that have proved to be effective and safe in adequately powered, prospective, placebo-controlled trials are lacking. This unmet need is due to the incompletely understood pathogenesis of the disease.
1
Current treatments are inconsistently beneficial and often associated with side effects, and their modification of the ultimate disease outcome is uncertain.
1
–
3
Previous clinical trials, which were rarely placebo-controlled, suggest that high-dose glucocorticoids, alone
3
–
5
or with radiotherapy,
6
,
7
can reduce inflammation-related signs and symptoms in patients with active ophthalmopathy. However, glucocorticoids and orbital radiotherapy minimally affect proptosis and can cause dose-limiting adverse . . .
الناشر
Massachusetts Medical Society
موضوع
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Female
/ Graves Ophthalmopathy - complications
/ Graves Ophthalmopathy - drug therapy
/ Humans
/ Hyperglycemia - chemically induced
/ Immunologic Factors - adverse effects
/ Immunologic Factors - therapeutic use
/ Male
